

## **GA<sup>2</sup>FA 2025**

# **ANAPHYLAXIS RESEARCH SYMPOSIUM**

## **Thursday 11<sup>th</sup> September 2025**

### **8.30am-12.30pm**

We are delighted to announce a special research symposium at the 3<sup>rd</sup> GA<sup>2</sup>FA meeting. This will take place on the morning on 11<sup>th</sup> September. The aim is to build a potential anaphylaxis network to train the next generation of researchers in Europe.

We invite short (10min) presentations of unpublished data on the following themes;

- How epidemiology can provide mechanistic insights
- Diagnosis / Prognosis
- Mechanisms
- Towards improvements in management

Postdoctoral Fellows and PhD students in the 3<sup>rd</sup>+ year are particularly encouraged to apply. This is a great opportunity for you to share your knowledge, have their poster presented in front of key opinion leaders in the field and be acknowledged as active contributors in the GA<sup>2</sup>FA 2025 Forum.

**All presenters will benefit from the early registration fee at the term of their abstract acceptance**

### **Submission rules:**

The abstract must have a short, specific title (no abbreviations). The main text should be 950 characters (about 300-350 words). This includes the text plus any graphics, but not the title or authors.

For the Anaphylaxis Symposium, case reports will not be considered.

The use of trademarks is prohibited, only International Non-proprietary Names (INN), e.g. generic drug names, are allowed.

Indicate minimum 2, maximum 3 keywords which best correspond to the content of your research topic. All abstracts must be submitted in English with accurate grammar and spelling suitable for publication.

As it is in the intent of Global Allergy and Asthma Excellence Network to provide high-quality sessions focused on educational content that is free from commercial influence or bias, all potential conflicts of interest need to be declared.

### **Presentation format**

Presentations will be limited to 10mins (oral), accompanied by a Powerpoint presentation.

Presenters are also welcome to submit an optional poster to accompany the oral presentation, to be submitted in a PDF format. These will be displayed in the main GAFA Poster session. If you wish your presentation to be considered for an award, you will need to also prepare a poster.

It is advisable to structure the poster in the following sections, following the logical order of evolution:

### **Authors**

The first author (=presenting author) is responsible for the content and is the contact person for communication purposes and dissemination of information to co-authors.

- First author and co-authors need to provide their: full name and affiliation.
- Ensure that all authors complete the “Conflict of Interest” statement identifying any financial interest in products or processes involved in their activities.

### **Submission date**

Abstract submission by email to: [gafa.scientific@ga2len.network](mailto:gafa.scientific@ga2len.network) will remain open **until 20<sup>th</sup> July 2025**, and abstracts can be edited until this time.

### **Selection of Posters**

All submissions will be peer-reviewed by a panel of three experts in the field of anaphylaxis (Scientific Programme Committee), and scored to determine which are accepted/rejected.

Notification of acceptance/non-acceptance status will be communicated **29<sup>th</sup> July 2025**. Please ensure that the email provided for the presenting author is accurate as all correspondences will be sent via email, to the presenting author.

If you wish your presentation to be considered for an award, you will need to also prepare a poster. The Scientific Programme Committee and meeting attendees will vote the best poster based on the following criteria:

- Originality
- Novelty
- Clarity of conclusions according to methodology and results
- Duration of the presentation (in compliance with the submission rules)
- Quality of the oral presentation performance

### **Awards**

There will be 6 prizes of a 300 Euro:

- 3 for the best poster voted by the Scientific Programme Committee and
- 3 for the best poster voted by the audience.

### **Data protection**

Participants authorize Global Allergy and Asthma Excellence Network to capture the personal data (name, surname, position or job, image, and voice) during the participation in the clinical cases session.

Global Allergy and Asthma Excellence Network will carry out interviews, photographic reports/audio-visual/sound recordings on its own behalf or through a third party, through capturing images, sound, contributions, interpretations and/or recording by means of video or photography.

Therefore, participants grant Global Allergy and Asthma Excellence Network an irrevocably non-exclusive right to process and use its own image and personal data, in accordance with the provisions of Law 1/1982, of May 5, the Protection of the Right to Honour, Personal and Family Privacy and Own Image.

For this purpose, the participant gives its consent to the process and use its own image and personal data in accordance with the following clauses:

- a) The participant transfers to Global Allergy and Asthma Excellence Network the exploitation rights of the recorded images, for the maximum time allowed by law and for all countries in the world.
- b) The participant gives its consent, without limitation, to the following uses of its own image and name recorded by Global Allergy and Asthma Excellence Network using the technical means currently used and those that may be developed in the future:
  - i) Global Allergy and Asthma Excellence Network will use the recordings to publicize Global Allergy and Asthma Excellence Network internal activities. The recorded images will be used for promotional activities by Global Allergy and Asthma Excellence Network, in any of the possible formats, including exposure and promotion through the internet and on the different websites of Global Allergy and Asthma Excellence Network.

### **Further Information**

If you have any additional questions or need further information concerning poster submission, please contact:

ANACARE GA<sup>2</sup>FA 2025

Email: [gafa.scientific@ga2len.network](mailto:gafa.scientific@ga2len.network)